London (UK) February 17th, 2025 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), is a clinical-stage oncology biopharmaceutical company pioneering a novel class of cancer treatments. Vidac Pharma is honored to have been selected to present at the Southern California Chapter of Keiretsu Forum on February 27, 2025. Keiretsu, the world’s largest and most selective international angel investor network, offers its members access to rigorously vetted investment opportunities, making this an important milestone for Vidac Pharma
At the forum, Vidac Pharma will showcase its groundbreaking approach to drug development, which has enabled the company to create highly effective oncology and onco-dermatology drug candidates with minimal to no side effects.
Vidac Pharma has made significant strides in onco-dermatology, having successfully completed:
- Phase 2B clinical trials in Actinic Keratosis, a condition that can progress to Squamous Cell Carcinoma, a potentially metastatic cancer.
- Phase 2A trials in Cutaneous T-Cell Lymphoma (CTCL), a rare and challenging-to-treat cancer.
- A proof-of-concept study in brain cancer, conducted as part of a compassionate use program.
The company’s revolutionary technology is based on reversing the Warburg effect, a fundamental cancer mechanism first described by Nobel laureate Otto Warburg. This approach has demonstrated broad anti-cancer potential, as the Warburg effect is a universal trait across many tumor types.
As Vidac Pharma advances its clinical programs, it is actively expanding its capital and equity structure and seeking crossover funding to accelerate its transition to late-stage clinical development
For more information please contact:
Vidac Pharma Holding Plc
Dr Max Herzberg
20-22 Wenlock Road
London N1 7GU
United Kingdom
http://www.vidacpharma.com/
investors@vidacpharma.com
+972-54-4257381
About Vidac Pharma
Vidac Pharma is a clinical-stage biopharmaceutical company dedicated to discovering and developing first-in-class medicines to help people suffering from a range of oncologic and onco-dermatologic diseases. Vidac develops first-in-class anti-cancer drugs by modifying the hyper-glycolytic tumor microenvironment, targeting the overexpression and wrong anchoring of the Hexokinase 2 metabolic checkpoint (HK2) in cancer cells, to renormalize tumor microenvironment and selectively provoke their programmed death, without affecting surrounding normal tissue. VDA-1102, a first drug candidate of Vidac Pharma has shown to be effective against advanced Actinic Keratosis (AK), while interim results in Cutaneous T-cell Lymphoma (CTCL) yielded a positive effect in Phase 2 trials in humans.
Important information
The information in this press release does not constitute a public offer to sell or a solicitation to submit an offer to buy or subscribe to shares of Vidac Pharma Holding PLC, but is for informational purposes only. The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.